These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28969629)

  • 1. Decision support systems for incurable non-small cell lung cancer: a systematic review.
    Révész D; Engelhardt EG; Tamminga JJ; Schramel FMNH; Onwuteaka-Philipsen BD; van de Garde EMW; Steyerberg EW; Jansma EP; De Vet HCW; Coupé VMH
    BMC Med Inform Decis Mak; 2017 Oct; 17(1):144. PubMed ID: 28969629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer.
    Révész D; Engelhardt EG; Tamminga JJ; Schramel FMNH; Onwuteaka-Philipsen BD; van de Garde EMW; Steyerberg EW; de Vet HCW; Coupé VMH
    J Cancer Educ; 2020 Apr; 35(2):345-351. PubMed ID: 30685832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Usefulness of Tools to Support Decision-making for Palliative Treatment of Metastatic Colorectal Cancer: A Systematic Review.
    Engelhardt EG; Révész D; Tamminga HJ; Punt CJA; Koopman M; Onwuteaka-Philipsen BD; Steyerberg EW; Jansma IP; De Vet HCW; Coupé VMH
    Clin Colorectal Cancer; 2018 Mar; 17(1):e1-e12. PubMed ID: 28734786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid learning in practice: a lung cancer survival decision support system in routine patient care data.
    Dekker A; Vinod S; Holloway L; Oberije C; George A; Goozee G; Delaney GP; Lambin P; Thwaites D
    Radiother Oncol; 2014 Oct; 113(1):47-53. PubMed ID: 25241994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.
    Vickers AD; Winfree KB; Cuyun Carter G; Kiiskinen U; Jen MH; Stull D; Kaye JA; Carbone DP
    BMC Cancer; 2019 Apr; 19(1):353. PubMed ID: 30987609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
    J Clin Oncol; 1997 Aug; 15(8):2996-3018. PubMed ID: 9256144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
    Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP
    JAMA Oncol; 2017 Jun; 3(6):827-831. PubMed ID: 27892978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inventory of oncologists' unmet needs for tools to support decision-making about palliative treatment for metastatic colorectal cancer.
    Engelhardt EG; Révész D; Tamminga HJ; Punt CJA; Koopman M; Onwuteaka-Philipsen BD; Steyerberg EW; de Vet HCW; Coupé VMH
    BMC Med Inform Decis Mak; 2018 Dec; 18(1):132. PubMed ID: 30551735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
    Chayab L; Konstantelos N; Leighl NB; Tadrous M; Wong WWL
    Pharmacoeconomics; 2023 Aug; 41(8):945-980. PubMed ID: 37268866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.
    Brule SY; Al-Baimani K; Jonker H; Zhang T; Nicholas G; Goss G; Laurie SA; Wheatley-Price P
    Lung Cancer; 2016 Jul; 97():15-21. PubMed ID: 27237022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a Deep Learning Model for Non-Small Cell Lung Cancer Survival.
    She Y; Jin Z; Wu J; Deng J; Zhang L; Su H; Jiang G; Liu H; Xie D; Cao N; Ren Y; Chen C
    JAMA Netw Open; 2020 Jun; 3(6):e205842. PubMed ID: 32492161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer.
    Jackman DM; Zhang Y; Dalby C; Nguyen T; Nagle J; Lydon CA; Rabin MS; McNiff KK; Fraile B; Jacobson JO
    J Oncol Pract; 2017 Apr; 13(4):e346-e352. PubMed ID: 28260402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External Validation of a Prognostic Score for Patients Receiving Palliative Thoracic Radiotherapy for Lung Cancer.
    Nieder C; Tollåli T; Haukland E; Reigstad A; Flatøy LR; Dalhaug A
    Clin Lung Cancer; 2017 Jul; 18(4):e297-e301. PubMed ID: 28189593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
    Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
    JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
    Ashworth A; Rodrigues G; Boldt G; Palma D
    Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary therapeutic decision-making in inoperable non-small cell lung cancer.
    Erkurt E; Tunali C; Erkişi M
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):439-44. PubMed ID: 10661352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage III non-small-cell lung cancer: Establishing a benchmark for the proportion of patients suitable for radical treatment.
    Al-Shamsi HO; Al Farsi A; Ellis PM
    Clin Lung Cancer; 2014 Jul; 15(4):274-80. PubMed ID: 24685356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
    Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
    Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinician perspectives on clinical decision support systems in lung cancer: Implications for shared decision-making.
    Ankolekar A; van der Heijden B; Dekker A; Roumen C; De Ruysscher D; Reymen B; Berlanga A; Oberije C; Fijten R
    Health Expect; 2022 Aug; 25(4):1342-1351. PubMed ID: 35535474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.
    Wu SY; Lazar AA; Gubens MA; Blakely CM; Gottschalk AR; Jablons DM; Jahan TM; Wang VEH; Dunbar TL; Wong ML; Chan JW; Guthrie W; Belkora J; Yom SS
    JAMA Netw Open; 2020 Sep; 3(9):e209750. PubMed ID: 32997124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.